New ECT technique aims to zap depression without the memory loss

NCT ID NCT04099342

Terminated Symptom relief Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way of doing electroconvulsive therapy (ECT) for people with treatment-resistant depression. The goal is to target the brain more precisely to reduce side effects like memory loss while still helping with depression. Twenty participants will receive the new FEAST treatment, and researchers will measure seizure activity and mood changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FEAST (focally electrically-administered seizure therapy) device
What this could lead to: If successful, this could lead to a version of ECT that treats depression effectively but causes less memory loss.
What could go wrong: This is a small, early-stage study (20 participants) that is currently suspended. The new method may not work as well as standard ECT, and memory loss risks may still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT RESISTANT DEPRESSION

Contacts and locations

Locations

University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.